JAGSONPAL PHARMACEUTICALS LTD. received a warning letter from the USFDA on February 5, 2025, due to CGMP deviations; this may impact sales amounting to INR 3.5 Cr, which is 1.46% of current fiscal year sales.
AI Assistant
Jagsonpal Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.